See feature article below on: ONCS
About Broad Street Alerts:
Big opportunities in Small Cap’s
Broadstreetalerts.com recent profiles and track record, 157% in verifiable potential gains for our
members in December 2015 alone.
December 29th, 2015- (NASDAQ: INVT) opened $1.35/share hit a high midday of $2.82/share over 100%
in gains for our members.
December 15th, 2015-(NYSE-MKT: XXII) opened at $1.29 hit a high of $1.54 within 3 days for gains of
19% for our members.
December 2nd, 2015- (NASDAQ: TCCO) opened at $3.25 hit a high of $4.50 within 3 days for 38% gains
for our members.
February 14th, 2015 ETN report on 3x velocity shares Crude oil (NYSEMKT: UWTI) at $15.50/share up
nearly 100% in a little over a month for our members.
These are numbers that make traders drool. Any trader in any market would fall all over themselves to
see numbers like this. So if you’ve been on the fence, perhaps it’s time to start doing some research and
verify our numbers for yourself. We are constantly raising the bar and separate ourselves from the rest
of the small-cap newsletters as the best in business. We know with a large following comes a large
responsibility as we have everyone from institutional investors to the beginner following our profiled
securities in our newsletters. This is something we take very seriously always seeking small cap growth
companies that have both near and long-term potential for our members.
***Get our small cap profiles, special situation and watch alerts in real time. We are now offering our
VIP SMS/text alert service for free, simply text the word “Alerts” to the phone number 25827 from your
Shares of OncoSec Medical Inc (NASDAQ:ONCS) have earned an average broker rating score of 1.00 (Strong Buy) from the four analysts that provide coverage for the company, Zacks Investment Research reports. Four investment analysts have rated the stock with a strong buy recommendation.
Brokers have set a 1-year consensus target price of $14.25 for the company and are predicting that the company will post ($0.43) earnings per share for the current quarter, according to Zacks. Zacks has also given OncoSec Medical an industry rank of 73 out of 265 based on the ratings given to related companies.
ONCS has been the subject of a number of analyst reports. Zacks Investment Research reissued an “outperform” rating on shares of OncoSec Medical in a research report on Thursday, March 3rd. HC Wainwright lowered their price target on OncoSec Medical from $25.00 to $17.00 and set a “buy” rating for the company in a research report on Monday, March 7th. Finally, Maxim Group reissued a “buy” rating and issued a $17.00 price target on shares of OncoSec Medical in a research report on Wednesday, March 9th.
Shares of OncoSec Medical (NASDAQ:ONCS) opened at 2.57 on Thursday. The company’s market cap is $43.62 million. OncoSec Medical has a 52-week low of $1.36 and a 52-week high of $8.40. The company’s 50-day moving average is $1.83 and its 200 day moving average is $3.23.
OncoSec Medical (NASDAQ:ONCS) last released its quarterly earnings results on Tuesday, March 8th. The company reported ($0.42) EPS for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.04. On average, analysts anticipate that OncoSec Medical will post ($1.72) EPS for the current year.
A hedge fund recently bought a new stake in OncoSec Medical stock. Gierl Augustine Investment Management bought a new stake in shares of OncoSec Medical Inc (NASDAQ:ONCS) during the fourth quarter, according to its most recent disclosure with the SEC. The fund bought 200 shares of the company’s stock, valued at approximately $0.
OncoSec Medical Incorporated is a biotechnology company focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate and guide an anti-tumor immune response for the treatment of cancer. The Company’s portfolio includes biologic immunology therapeutic product candidates intended to treat a range of tumor types.
Source: South Florida Hedge Fund Managers